In oncology, the saying, “Change is the only constant,” feels inadequate. A more fitting perspective is – “Change is not just a constant; it’s a revolution!”
Cancer treatments that were once celebrated as breakthroughs are steadily being replaced or enhanced by next-gen therapies. For oncologists, keeping up with these developments is both an opportunity and a challenge.
The emergence of targeted therapies, such as Tyrosine Kinase Inhibitors (TKIs), has introduced a new level of precision in cancer treatment, enabling oncologists to target cancer cells while minimizing damage to healthy tissue effectively. However, the array of clinical trials in the pipeline offers even more powerful therapies with the promise of better outcomes and fewer side effects.
In situations like this, where there is a palpable tug-of-war between the present (existing treatments) and the future (upcoming treatments), oncologists must dig deeper, think critically, and make pivotal decisions regarding treatment selection. They must carefully balance their patients’ immediate needs against the potential advantages of emerging therapies, weighing the various factors that influence these decisions.
Tyrosine Kinase Inhibitors (TKIs) – Are They Promising?
Yes, they are! While chemotherapy has long been a cornerstone of cancer treatment, often acting on rapidly dividing cells indiscriminately, TKIs are revolutionizing the approach to cancer care. So, what makes TKIs such game-changers in the fight against cancer? It all boils down to their ability to zero in on specific enzymes known as ‘tyrosine kinases,’ which play a critical role in driving the growth and spread of cancer cells.
TKIs empower oncologists to disrupt the intricate signaling pathways cancer cells rely on to thrive and multiply while sparing surrounding healthy tissues. This precision in targeting means that patients often experience fewer side effects compared to traditional chemotherapy, making their treatment journey more manageable and less burdensome.
But it doesn’t stop there. For many patients, the emergence of TKIs signifies more than just a different treatment procedure. It opens the door to the possibility of improved outcomes. Patients may find themselves experiencing not only better control over their disease but also an enhanced quality of life throughout their battle with cancer.
Survey Data Reveals Oncologists’ Strong Interest in Tyrosine Kinase Inhibitors (TKIs)
By now, you know why and how TKIs have become integral to oncology. But how about we spill some more beans (insights) that will enlighten you about what Oncologists think about this treatment method? Keep reading!
1. Awareness of Emerging Treatments
Needless to say, awareness is the foundation of advancing cancer care. For oncologists, staying informed about new therapies opens doors to innovative treatment approaches that can profoundly impact patient outcomes.

It’s encouraging to see that 82% of oncologists are already well-versed in the latest TKI treatments progressing through clinical trials. This commitment to ongoing learning highlights how dedicated the oncology community is to treating cancer and embracing advancements that could redefine patient care.
2. Engagement with Leading Pharmaceutical Brands
The relationship between oncologists and pharmaceutical companies is crucial in advancing cancer care. These partnerships provide oncologists access to effective treatment options and open doors for collaboration on clinical trials and research, which drive the development of innovative therapies.

Nearly half (47%) of oncologists are aligned with AstraZeneca and Novartis for their TKI offerings, reflecting their trust in these industry leaders. Such connections ensure oncologists have the support and resources to deliver high-quality patient care and stay at the forefront of medical advancements.
3. Common Prescription Patterns
Regarding clinical practice, approximately 40% of oncologists commonly prescribe Tagrisso and Gleevec.

The decision to prescribe these medications often stems from their proven efficacy and the oncologists’ familiarity with their benefits and side effects. By integrating these therapies into their practice, oncologists are actively contributing to better cancer management, reflecting their understanding of the importance of targeted treatments in oncology.
Emerging Cancer Treatment Options Beyond Tyrosine Kinase Inhibitors (TKIs)
While TKIs are creating quite a buzz in the oncology world, oncologists are also exploring a host of innovative therapies that target cancer in unique ways.
Here are a few notable examples:

Lynparza (Olaparib) | PARP Inhibitor
- Indication: Lynparza is primarily used for treating specific breast and ovarian cancers, particularly in patients with BRCA mutations.
- Mechanism of Action: This innovative therapy disrupts the cancer cells’ ability to repair DNA, leading to cell death, especially in those cells already weakened in their repair mechanisms. By specifically targeting DNA repair processes, PARP inhibitors like Lynparza provide a focused approach to managing difficult-to-treat cancers, allowing oncologists to offer more personalized treatment strategies to their patients.
Epkinly (Epcoritamab) | Bispecific T-cell Engager (BiTE)
- Indication: Epkinly is approved for use in certain blood cancers, including diffuse large B-cell lymphoma (DLBCL).
- Mechanism of Action: This therapy binds to CD20 on B cells and CD3 on T cells, effectively steering the immune system to recognize and destroy cancer cells. The BiTE approach significantly enhances the body’s immune response against cancer, representing a powerful immunotherapy option for certain hematological malignancies. By leveraging the patient’s immune system, oncologists can create more robust treatment plans.
Rituxan (Rituximab) | Monoclonal Antibody
- Indication: Rituxan is commonly used for treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
- Mechanism of Action: This monoclonal antibody specifically targets CD20 on B cells, marking these cells for destruction by the immune system. By aiding the immune system in identifying and attacking cancerous B cells, Rituxan helps to improve outcomes for patients with specific lymphomas and leukemias.
These therapies highlight the growing diversity of treatment options available to oncologists. By focusing on various molecular targets and leveraging the immune system innovatively, they enhance the potential for more effective and tailored cancer treatments.
Including these therapies alongside TKIs enriches the oncology toolkit, empowering physicians to adopt a broader range of strategies that address the complexities of different cancer types. As a result, patients benefit from more personalized care that aligns with their specific cancer profiles, ultimately improving their chances of successful outcomes.
Need of the Hour – Striking the Right Balance
The future of cancer care is filled with potential as oncologists balance established treatments with emerging therapies.
Every new therapy under trial offers hope for improved outcomes and a better quality of life. Oncologists are challenged to integrate these advancements while respecting the tried-and-true treatments that have comforted patients for years. This balancing act (instead of a tug-of-war) requires expertise and an unwavering commitment to patient well-being.
As we look ahead, the question isn’t just how oncologists will adapt. Instead, it’s more about how they will continue to lead the charge in redefining what’s possible in cancer treatment. The revolution in oncology is not just about the medications – it’s about hope, resilience, and the relentless pursuit of a cure. Together, they are charting a course towards a future where cancer care is more personalized, effective, and compassionate than ever before.
The journey is just beginning, and the possibilities are limitless!